Posted on

cbd topical clinical trials

Side effects of CBD include nausea, fatigue and irritability. CBD can increase the level in your blood of the blood thinner coumadin, and it can raise levels of certain other medications in your blood by the exact same mechanism that grapefruit juice does. A significant safety concern with CBD is that it is primarily marketed and sold as a supplement, not a medication. Currently, the FDA does not regulate the safety and purity of dietary supplements. So, you cannot know for sure that the product you buy has active ingredients at the dose listed on the label. In addition, the product may contain other (unknown) elements. We also don’t know the most effective therapeutic dose of CBD for any particular medical condition.

Some CBD manufacturers have come under government scrutiny for wild, indefensible claims, such that CBD is a cure-all for cancer, which it is not. We need more research but CBD may be prove to be an option for managing anxiety, insomnia, and chronic pain. Without sufficient high-quality evidence in human studies we can’t pinpoint effective doses, and because CBD is currently is mostly available as an unregulated supplement, it’s difficult to know exactly what you are getting. If you decide to try CBD, talk with your doctor — if for no other reason than to make sure it won’t affect other medications you are taking.

CBD is commonly used to address anxiety, and for patients who suffer through the misery of insomnia, studies suggest that CBD may help with both falling asleep and staying asleep.

Is CBD safe?

CBD has been touted for a wide variety of health issues, but the strongest scientific evidence is for its effectiveness in treating some of the cruelest childhood epilepsy syndromes, such as Dravet syndrome and Lennox-Gastaut syndrome (LGS), which typically don’t respond to antiseizure medications. In numerous studies, CBD was able to reduce the number of seizures, and, in some cases, it was able to stop them altogether. Videos of the effects of CBD on these children and their seizures are readily available on the Internet for viewing, and they are quite striking. Recently the FDA approved the first ever cannabis-derived medicine for these conditions, Epidiolex, which contains CBD.

CBD may offer an option for treating different types of chronic pain. A study from the European Journal of Pain showed, using an animal model, CBD applied on the skin could help lower pain and inflammation due to arthritis. Another study demonstrated the mechanism by which CBD inhibits inflammatory and neuropathic pain, two of the most difficult types of chronic pain to treat. More study in humans is needed in this area to substantiate the claims of CBD proponents about pain control.

Cannabidiol (CBD) has been recently covered in the media, and you may have even seen it as an add-in booster to your post-workout smoothie or morning coffee. What exactly is CBD? Why is it suddenly so popular?

CBD is readily obtainable in most parts of the United States, though its exact legal status is in flux. All 50 states have laws legalizing CBD with varying degrees of restriction, and while the federal government still considers CBD in the same class as marijuana, it doesn’t habitually enforce against it. In December 2015, the FDA eased the regulatory requirements to allow researchers to conduct CBD trials. Currently, many people obtain CBD online without a medical cannabis license. The government’s position on CBD is confusing, and depends in part on whether the CBD comes from hemp or marijuana. The legality of CBD is expected to change, as there is currently bipartisan consensus in Congress to make the hemp crop legal which would, for all intents and purposes, make CBD difficult to prohibit.

When compared to the TPA control group (group 2), treatment with CBD and PEA and treatment with mometasone both resulted in a significant difference in mean change in ear calliper at 24 and 48 hours.

Mice that were treated with mometasone furoate (corticosteroid) ointment showed a significant reduction in the difference between the left and right ear calliper, from maximum edema, after 8-, 24-, and 48-hours post-challenge period. In comparison, test product containing CBD (0.9%) and PEA yielded a smaller, yet still significant, reduction in the difference in ear calliper.

Preparations were applied only to the left ear of each mouse, with the right ear left untreated throughout. Prior to TPA application, the researchers measured/callipered the ears of each mouse and repeated this for the left and right ear of each mouse at 8, 24, and 48 hours to maximum ear swelling potential to assess the efficacy of mometasone and CBD/PEA treatments. This was achieved at the 8-hour calliper of the TPA control group (group 2).

Results of the study

A total of 35 male Swiss Webster mice were divided into four treatment groups. Group 1 was treated on the ear with TPA vehicle and received no further treatment, serving as a control group; group 2 mice were exposed to TPA and served as a control group for TPA treatment; group 3 mice were exposed to TPA and subsequently treated with topical corticosteroid, mometasone (0.1%); finally, group 4 mice were exposed to TPA and subsequently treated with the test product containing CBD (0.9%) and PEA.

12-O-tetradecanoylphorbol-13-acetate (TPA) is traditionally used to study various forms of inflammatory skin disorders such as AD, allergic contact dermatitis, and psoriasis. In this study, TPA-induced ear oedema (swelling) was utilised as the chosen model of skin inflammation.

Inflammatory skin conditions, such as Atopic Dermatitis, can become a significant burden on those affected and leading to several associated symptoms. Atopic Dermatitis or Atopic Eczema is believed to affect between 2.1% and 4.9% of the global adult population, with prevalence in the child population believed to be even higher.

For this study, researchers used a topical formulation of CBD in combination with palmitoylethanolamide (PEA) – with both ingredients being considered active ingredients of interest in this context. The topical was produced to Good Manufacturing Practice standards and is commercially available to customers. For comparison to standard treatment, researchers also used topical corticosteroid (mometasone 0.1% – a class III corticosteroid).

In 2018, Molecules published “Cannabinoid Delivery Systems for Pain and Inflammation Treatment,” which summarized some of the current research into topical and transdermal cannabinoids for these conditions.

But patients and consumers are not waiting for the results of clinical trials. Cannabinoids are already making their way into skincare lines and sports medicine. But beyond the over-the-counter market, what does the current body of study tell us about its true medicinal potential? Is there a viable future for cannabis within topical plant-based medicines?

Whether applied through a topical/transdermal application or more popular administration routes like inhaled and oral formulas, the human body interacts with cannabinoids via the endocannabinoid system. This system regulates many biological processes through a network of receptors and chemical neurotransmitters, such as pain, inflammation, mood, memory, and more.

Research into Topical Cannabis and Cannabinoids Limited

Still, there are a few preliminary studies, which have no doubt spawned some of these marketing campaigns. For example, in 2014, one study evidenced that CBD’s lipostatic, antiproliferative, and anti-inflammatory effects could benefit those with acne vulgaris. This early research now seems to have led to an observational clinical trial on the condition, sponsored by the CBD brand Charlotte’s Web.

From this perspective, pharmaceutical preparations working through the endocannabinoid system could offer relief for conditions like acne, itch, pain, psoriasis, systemic sclerosis, and cancer.

Consumers and researchers alike are intrigued by the possible medicinal benefits of topically applied cannabinoids, like tetrahydrocannabinol (THC) and cannabidiol (CBD). There is so much excitement, in fact, some analysts predict the cannabis topicals market will outpace the growth of the cannabis sector as a whole.

But, when applied topically, cannabinoids interact directly with the endocannabinoid receptors located in the skin. Thus, the endocannabinoid system is a novel new target for skin health and disease research.